| Code | CSB-RA023981MB16HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Telazorlimab, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes immunological memory. TNFRSF4 signaling is particularly relevant in cancer immunology, autoimmune diseases, and inflammatory conditions, where modulation of T cell activity can significantly impact disease progression and therapeutic outcomes.
Telazorlimab is an investigational agonistic antibody designed to stimulate TNFRSF4 signaling, thereby enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating OX40-mediated immunomodulation, exploring combination immunotherapy strategies, and studying T cell biology in various disease contexts. The antibody enables detailed examination of TNFRSF4's role in immune checkpoint modulation and its potential as a therapeutic target in oncology and immune-related disorders.
There are currently no reviews for this product.